Antonio Rossi

Summary

Country: Italy

Publications

  1. ncbi request reprint The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Città Ospedaliera, 83100 Avellino Italy
    Rev Recent Clin Trials 3:217-27. 2008
  2. doi request reprint Disparities in subgroup populations enrolled in lung cancer trials
    Antonio Rossi
    Division of Medical Oncology, SG Moscati Hospital, Contrada Amoretta, 8 83100, Avellino, Italy
    Expert Rev Respir Med 6:163-72. 2012
  3. doi request reprint Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data
    Antonio Rossi
    S G Moscati Hospital, Avellino, Città Ospedaliera, Contrada Amoretta, Avellino, Italy
    J Clin Oncol 30:1692-8. 2012
  4. doi request reprint Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Cancer Treat Rev 39:498-506. 2013
  5. doi request reprint Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Cancer Treat Rev 39:489-97. 2013
  6. ncbi request reprint Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta 8, Avellino, Italy
    Curr Drug Targets 11:865-8784. 2010
  7. ncbi request reprint Chemotherapy of advanced non-small cell lung cancer in elderly patients
    A Rossi
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Ann Oncol 17:ii58-60. 2006
  8. ncbi request reprint Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients
    Antonio Rossi
    U O Oncologia Medica, Azienda Ospedaliera S G Moscati, Avellino, Italy
    Expert Opin Drug Saf 4:1051-67. 2005
  9. ncbi request reprint Screening for lung cancer: New horizons?
    Antonio Rossi
    Unita Operativa di Oncologia Medica, Azienda Ospedaliera S G Moscati, Contrada Amoretta, Città Ospedaliera, 83100 Avellino, Italy
    Crit Rev Oncol Hematol 56:311-20. 2005
  10. ncbi request reprint Cetuximab in advanced non-small cell lung cancer
    Antonio Rossi
    Division of Medical Oncology, SG Moscati Hospital, Contrada Amoretta, Città Ospedaliera, Avellino, Italy
    Crit Rev Oncol Hematol 59:139-49. 2006

Detail Information

Publications94

  1. ncbi request reprint The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Città Ospedaliera, 83100 Avellino Italy
    Rev Recent Clin Trials 3:217-27. 2008
    ..This article will focus on cetuximab and other monoclonal antibodies and their applications in the treatment of advanced NSCLC...
  2. doi request reprint Disparities in subgroup populations enrolled in lung cancer trials
    Antonio Rossi
    Division of Medical Oncology, SG Moscati Hospital, Contrada Amoretta, 8 83100, Avellino, Italy
    Expert Rev Respir Med 6:163-72. 2012
    ..The impact of certain characteristics such as gender, ethnicity and age of patients enrolled in randomized trials on the final results has been examined and discussed in this article...
  3. doi request reprint Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data
    Antonio Rossi
    S G Moscati Hospital, Avellino, Città Ospedaliera, Contrada Amoretta, Avellino, Italy
    J Clin Oncol 30:1692-8. 2012
    ....
  4. doi request reprint Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Cancer Treat Rev 39:498-506. 2013
    ..Topotecan is effective as second-line treatment, although evidence on clinical benefit for patients relapsed after first-line is limited...
  5. doi request reprint Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Cancer Treat Rev 39:489-97. 2013
    ..This review will summarize the current evidence that strongly support the hypothesis that gefitinib, erlotinib and afatinib are ideal drugs for NSCLC patients carrying EGFR mutations...
  6. ncbi request reprint Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta 8, Avellino, Italy
    Curr Drug Targets 11:865-8784. 2010
    ..Here we review the current results and give an overview of some of the future developments of the main anti-VEGFR drugs in the treatment of NSCLC patients...
  7. ncbi request reprint Chemotherapy of advanced non-small cell lung cancer in elderly patients
    A Rossi
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Ann Oncol 17:ii58-60. 2006
    ..High priority should be also given to the evaluation of the role of new targeted therapies. Moreover, a comprehensive geriatric assessment for individualized treatment choice in NSCLC elderly patients is mandatory...
  8. ncbi request reprint Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients
    Antonio Rossi
    U O Oncologia Medica, Azienda Ospedaliera S G Moscati, Avellino, Italy
    Expert Opin Drug Saf 4:1051-67. 2005
    ..This review focuses on the currently-available evidences for the treatment of elderly patients affected by advanced NSCLC with regards to the role and safety of platinum-based chemotherapy...
  9. ncbi request reprint Screening for lung cancer: New horizons?
    Antonio Rossi
    Unita Operativa di Oncologia Medica, Azienda Ospedaliera S G Moscati, Contrada Amoretta, Città Ospedaliera, 83100 Avellino, Italy
    Crit Rev Oncol Hematol 56:311-20. 2005
    ..Further approaches to secondary prevention such as screening with positron emission tomography (PET), autofluorescence bronchoscopy and biomarkers hold great promise for the future...
  10. ncbi request reprint Cetuximab in advanced non-small cell lung cancer
    Antonio Rossi
    Division of Medical Oncology, SG Moscati Hospital, Contrada Amoretta, Città Ospedaliera, Avellino, Italy
    Crit Rev Oncol Hematol 59:139-49. 2006
    ..In the present paper we discuss about the activity, tolerability and efficacy of cetuximab, the EGFR monoclonal blocking antibody with the largest amount of clinical data being available on the treatment of advanced NSCLC...
  11. ncbi request reprint Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature
    Antonio Rossi
    UO Oncologia Medica, Azienda Ospedaliera San G Moscati, Avellino, Italy
    Oncology 64:353-60. 2003
    ..To test the activity of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in patients with colorectal cancer treated with adjuvant 5-fluorouracil (5-FU) plus leucovorin (LV) and suffering from mucositis...
  12. doi request reprint Biological prognostic and predictive factors in lung cancer
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Oncology 77:90-6. 2009
    ....
  13. ncbi request reprint Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer
    Antonio Rossi
    U O Oncologia Medica, Azienda Ospedaliera S G Moscati, Via Circumvallazione, 68, 83100, Avellino, Italy
    Anticancer Res 23:1657-64. 2003
    ..The ELVIS (Elderly Lung cancer Vinorelbine Italian Study) trial demonstrated the tolerability and efficacy of VNR in elderly pts with advanced non-small cell lung cancer (JNCI 91: 66-72, 1999)...
  14. ncbi request reprint New insights in drug development for the non-small cell lung cancer therapy
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Front Biosci 13:5108-19. 2008
    ..Aim of this review is to discuss about the new insights in targeted agents development for the treatment of NSCLC patients...
  15. ncbi request reprint Recent developments of targeted therapies in the treatment of non-small cell lung cancer
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Curr Drug Discov Technol 6:91-102. 2009
    ..This review shows the latest and the future developments of erlotinib, bevacizumab and ZD6474 in the treatment of advanced NSCLC patients...
  16. doi request reprint New avenues for second-line treatment of metastatic non-small-cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Expert Rev Anticancer Ther 9:115-24. 2009
    ..Phase III trials with these agents are ongoing...
  17. ncbi request reprint A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Clin Lung Cancer 8:396-8. 2007
    ..The study will enroll 100 patients: 58 patients aged >or= 70 years with a PS of 0-2 and 42 patients aged < 70 years with a PS of 2. The analysis will be conducted differently for the 2 groups of patients...
  18. ncbi request reprint Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 2:758-61. 2007
    ..We report the cases of three patients with advanced non-small cell lung cancer responding to erlotinib after progression under gefitinib treatment...
  19. ncbi request reprint Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Oncologist 12:191-200. 2007
    ..Their mechanism of action, preclinical data, and phase II studies suggest efficacy in the treatment of advanced NSCLC...
  20. ncbi request reprint Factors driving the choice of the best second-line treatment of advanced NSCLC
    Paolo Maione
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta 83100 Avellino, Italy
    Rev Recent Clin Trials 6:44-51. 2011
    ..Thus, more than in the past, first and second-line treatment of advanced NSCLC are linked, and the choice of second-line treatment is part of a strategy decided when beginning the first-line treatment...
  21. doi request reprint Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial
    Cesare Gridelli
    Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy
    J Thorac Oncol 7:233-42. 2012
    ..Treatment of elderly patients with small cell lung cancer (SCLC) is based on scanty evidence...
  22. ncbi request reprint Erlotinib in the treatment of non-small cell lung cancer: current status and future developments
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Anticancer Res 30:1301-10. 2010
    ..The present review discusses the role of erlotinib in the treatment of NSCLC...
  23. doi request reprint Treatment of advanced non-small-cell lung cancer in the elderly
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta 83100, Avellino, Italy
    Lung Cancer 66:282-6. 2009
    ..Further specifically designed phase III randomized trials are needed to optimize medical treatment of NSCLC in elderly patients...
  24. doi request reprint First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial
    Cesare Gridelli
    S G Moscati Hospital, Avellino, Italy
    J Clin Oncol 30:3002-11. 2012
    ..A randomized phase III trial was designed to test whether first-line erlotinib followed at progression by cisplatin-gemcitabine was not inferior in terms of survival to the standard inverse sequence...
  25. doi request reprint Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer
    Paola Claudia Sacco
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Target Oncol 6:171-80. 2011
    ..In the present review we discuss the rationale and the feasibility of these combinations and the first results available from clinical trials...
  26. ncbi request reprint The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 8, 83100 Avellino, Italy
    Curr Med Chem 17:1030-8. 2010
    ..This review will discuss these new evidences in the first-line treatment of advanced NSCLC and their implication in the current clinical decision-making...
  27. ncbi request reprint Non-small cell lung cancer therapy in the elderly
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, 83100 Avellino, Italy
    Clin Adv Hematol Oncol 9:375-83. 2011
    ..Future trials, specifically in the elderly population, should include these kinds of evaluations. The most recent therapies for the treatment of elderly patients with NSCLC will be discussed here...
  28. ncbi request reprint Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study
    Cesare Gridelli
    Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy
    Lancet Oncol 8:500-12. 2007
    ..We aimed to assess whether the addition of rofecoxib or PCI gemcitabine could improve overall survival compared with first-line treatment with cisplatin plus gemcitabine given by standard infusion...
  29. doi request reprint Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Oncologist 14:909-20. 2009
    ..This paper reviews the main clinical trials involving several different cancer vaccines employed in the treatment of early and advanced stage NSCLC, focusing on those in advanced stages of development...
  30. doi request reprint A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Città Ospedaliera, Contrada Amoretta, Avellino, Italy
    Clin Lung Cancer 8:568-71. 2007
    ..Based on the statistical design, the investigators plan to enroll 92 elderly patients, 46 per arm...
  31. ncbi request reprint Erlotinib in non-small-cell lung cancer
    Cesare Gridelli
    S G Moscati Hospital, Division of Medical Oncology, Città Ospedaliera, Contrada Amoretta, 83100 Avellino, Italy
    Expert Opin Pharmacother 8:2579-92. 2007
    ..Further investigations are ongoing to contribute to our understanding of the role of erlotinib in NSCLC treatment...
  32. doi request reprint Non-small-cell lung carcinoma vaccines in clinical trials
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Expert Rev Vaccines 10:887-97. 2011
    ..This article discusses the Phase I, II and III trials investigating the most promising vaccines in the treatment of patients affected by any stage of NSCLC, thus providing a perspective on the future of this approach in this setting...
  33. ncbi request reprint The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 8, 83100 Avellino, Italy
    Rev Recent Clin Trials 8:23-8. 2013
    ..Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction for patients selected for a maintenance strategy is recommended as first-line treatment of advanced non-squamous NSCLC...
  34. ncbi request reprint Lung cancer in the elderly
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Clin Oncol 25:1898-907. 2007
    ..Elderly patients often have comorbidities and other characteristics that make the selection of treatment daunting...
  35. doi request reprint Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rat
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Avellino, Italy
    Clin Lung Cancer 12:407-11. 2011
    ....
  36. ncbi request reprint Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases
    Antonio Rossi
    Unita Operativa di Oncologia Medica, Azienda Ospedaliera S G Moscati, Via Circumvallazione 68, 83100 Avellino, Italy
    Lung Cancer 47:421-3. 2005
    ..Comorbidities often contraindicate any chemotherapy in non-small cell lung cancer (NSCLC) patients, even single-agent one. This is the case of chronic renal failure...
  37. doi request reprint The role of maintenance treatment in advanced non-small-cell lung cancer: reality or early second line?
    Cesare Gridelli
    Division of Medical Oncology, San Giuseppe Moscati Hospital, Avellino, Italy
    Clin Lung Cancer 11:374-82. 2010
    ..Here, we attempt to define the different approaches that fall under the rubric of maintenance strategy, and discuss the results available to date...
  38. doi request reprint Pemetrexed in the treatment of advanced non-squamous lung cancer
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Lung Cancer 66:141-9. 2009
    ..This review shows the latest and indicates the future developments of pemetrexed in the treatment of advanced NSCLC patients...
  39. ncbi request reprint Treatment of small cell lung cancer in the elderly
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Città Ospedaliera 83100, Avellino, Italy
    Oncologist 10:399-411. 2005
    ..This review focuses on the main issues in the treatment of elderly SCLC patients...
  40. doi request reprint The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer
    Cesare Gridelli
    SG Moscati Hospital, Division of Medical Oncology, Avellino, Italy
    Expert Opin Investig Drugs 19:631-9. 2010
    ..NSCLC accounts for > 80% of all lung cancers. The treatment of advanced fit NSCLC patients seems to have reached a plateau. Considerable efforts have been initiated to identify new biological agents...
  41. doi request reprint The potential role of mTOR inhibitors in non-small cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Oncologist 13:139-47. 2008
    ..Here, we review the basic structure of the pathway together with current results and future developments of mTOR inhibitors in the treatment of NSCLC patients...
  42. ncbi request reprint Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Oncologist 14:137-47. 2009
    ..Further studies are warranted to establish the role of maintenance chemotherapy in patients with advanced NSCLC...
  43. doi request reprint Pemetrexed in advanced non-small cell lung cancer
    Cesare Gridelli
    S G Moscati Hospital, Division of Medical Oncology, Contrada Amoretta, 83100 Avellino, Italy
    Expert Opin Drug Saf 10:311-7. 2011
    ..The chemotherapeutic agent pemetrexed has produced, in the last years, an innovation of therapeutic algorithms of this disease, and this review is aimed at describing the role of pemetrexed in the treatment of NSCLC...
  44. doi request reprint New targeted therapies and small-cell lung cancer
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Clin Lung Cancer 9:271-9. 2008
    ..This review will focus on the reported results and the future development of the main novel biologic agents for the treatment of patients with SCLC...
  45. ncbi request reprint Erlotinib in non-small cell lung cancer treatment: current status and future development
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Città Ospedaliera, Contrada Amoretta, Avellino, Italy
    Oncologist 12:840-9. 2007
    ....
  46. ncbi request reprint The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients
    Cesare Gridelli
    Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy
    Lung Cancer 61:67-72. 2008
    ..Aim of this study is to describe activity and toxicity of single-agent gemcitabine given as prolonged infusion in the treatment of elderly patients with advanced NSCLC...
  47. ncbi request reprint Treatment of stage I-III non-small-cell lung cancer in the elderly
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Avellino, Italy
    Oncology (Williston Park) 20:373-80; discussion 385-6, 388, 393 passim. 2006
    ..Only specifically designed prospective studies will elucidate the real role and feasibility of this combined approach in the treatment of unselected elderly patients...
  48. ncbi request reprint The role of targeted therapy in non-small cell lung cancer
    Paolo Maione
    Unité Opertive di Oncologia Medica, S G Moscati Hospital, Via Circumvallazione 68, 83100 Avellino, Italy
    Crit Rev Oncol Hematol 51:29-44. 2004
    ..Moreover, important lessons can be learned from this first generation of clinical trials...
  49. doi request reprint Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Contrada Amoretta, Città Ospedaliera, 83100 Avellino, Italy
    Oncologist 14:612-20. 2009
    ....
  50. pmc The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer
    Clorinda Schettino
    Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi and A Lanzara, Second University of Naples, Italy Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Ther Adv Med Oncol 1:5-13. 2009
    ....
  51. ncbi request reprint ALK inhibitors and advanced non-small cell lung cancer (Review)
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Int J Oncol 45:499-508. 2014
    ..This review discusses ALK rearrangements, the clinical development and use of crizotinib, and other ALK-TKIs in advanced NSCLC. ..
  52. ncbi request reprint New molecular targets in the treatment of NSCLC
    Clorinda Schettino
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Curr Pharm Des 19:5333-43. 2013
    ..This review will focus on the role of EGFR, ALK, MET, and PI3K inhibitors in the treatment of NSCLC. ..
  53. ncbi request reprint Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly s
    Paolo Maione
    S Giuseppe Moscati Hospital, Avellino, Italy
    J Clin Oncol 23:6865-72. 2005
    ..To study the prognostic value for overall survival of baseline assessment of functional status, comorbidity, and quality of life (QoL) in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy...
  54. doi request reprint Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)
    Giuseppe Luigi Banna
    Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy
    Lung Cancer 73:78-88. 2011
    ..Post-operative radiotherapy (RT) is optional for pN2 tumours...
  55. doi request reprint Advances in chemotherapy in advanced non-small-cell lung cancer
    Paolo Maione
    S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Expert Opin Pharmacother 11:2997-3007. 2010
    ..Non-small-cell lung cancer (NSCLC) accounts for about 85% of all lung cancers diagnosis, and the majority of people diagnosed with NSCLC have advanced disease...
  56. doi request reprint Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-ce
    Cesare Gridelli
    Division of Medical Oncology, San Giuseppe Moscati Hospital, Avellino, Italy
    Clin Lung Cancer 12:70-3. 2011
    ..In addition, translational research evaluating EGFR and KRAS mutational status will be investigated for both arms...
  57. doi request reprint Management of unfit older patients with advanced NSCLC
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta 83100, Avellino, Italy
    Cancer Treat Rev 35:517-21. 2009
    ..However, specific prospective investigation is absolutely warranted for this special population...
  58. ncbi request reprint Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Via Circumvallazione, Avellino, 83100, Italy
    Oncogene 22:6629-38. 2003
    ..However, important lessons can be learned from this first generation of clinical trials that should be considered the first step of clinical research in this field...
  59. ncbi request reprint Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly
    Cesare Gridelli
    Division of Medical Oncology, San Giuseppe Moscati Hospital, Avellino, Italy
    Cancer 101:1733-44. 2004
    ..For such elderly patients, alternatives to conventional chemotherapy, such as novel molecularly targeted therapy regimens, are of interest...
  60. doi request reprint Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials
    Cesare Gridelli
    Oncologia Medica, Az Sanitaria S Giuseppe Moscati, Avellino, Contrada Amoretta 83100, Italy
    Lung Cancer 67:86-92. 2010
    ..Two parallel randomized phase 2 trials were performed to choose the optimal way of combining cetuximab with gemcitabine in the first-line treatment of elderly (CALC1-E) and adult PS2 (CALC1-PS2) patients with advanced NSCLC...
  61. ncbi request reprint Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program
    Cesare Gridelli
    UO Oncologia Medica, Azienda Ospedaliera S G Moscati, Avellino, Italy
    Anticancer Res 24:1873-7. 2004
    ..To evaluate the tolerabiliy and activity of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small cell lung cancer (NSCLC)...
  62. ncbi request reprint Oral cytotoxic drugs
    Cesare Gridelli
    UO Oncologia Medica, AO San G Moscati, Avellino, Italy
    Suppl Tumori 1:S19-23. 2002
  63. pmc Treating advanced non-small cell lung cancer in the elderly
    Paolo Maione
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Ther Adv Med Oncol 2:251-60. 2010
    ..Further specifically designed clinical trials are needed to optimize medical treatment of NSCLC in elderly patients...
  64. ncbi request reprint The PI3k inhibitors: new hopes in the battle against advanced NSCLC
    Paola Claudia Sacco
    Department of Oncology, S G Moscati Hospital of Avellino, C da Amoretta, 83100 Avellino, Italy
    Front Biosci (Landmark Ed) 19:259-71. 2014
    ..These mutations are observed in 2-5 % of non-squamous NSCLC and 8-10 % of squamous NSCLC. In this paper, we describe the available data and the possible future role of PI3k inhibitors in the treatment of advanced NSCLC. ..
  65. ncbi request reprint The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Oncologist 12:1183-93. 2007
    ....
  66. doi request reprint The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Crit Rev Oncol Hematol 68:29-36. 2008
    ..Here, we discuss about the potential role of HDAC inhibitors focusing on their activity, tolerability, efficacy and future development, in the treatment of NSCLC...
  67. doi request reprint Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Contrada Amoretta, Città Ospedaliera, 83100 Avellino, Italy
    Oncologist 14:601-11. 2009
    ..Other anti-EGFR monoclonal antibodies, such as panitumumab, matuzumab, nimotuzumab, and ch806, are in different stages of development for the treatment of advanced NSCLC...
  68. pmc Treatment of advanced non small cell lung cancer
    Maria Anna Bareschino
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Dis 3:122-33. 2011
    ..This review will discuss the different therapeutic options for first and second line treatment in the clinical practice...
  69. ncbi request reprint Complete response of severe symptomatic bone marrow metastases from heavily pretreated breast cancer with a 3-weekly trastuzumab schedule. A clinical case
    Antonio Rossi
    U O Oncologia Medica, Azienda Ospedaliera S G Moscati, Avellino, Italy
    Anticancer Res 24:317-9. 2004
    ..We report a case of a complete response of bone marrow metastases from breast cancer using a 3-weekly trastuzumab schedule, in a heavily pretreated patient with severe symptomatic pancytopenia...
  70. doi request reprint Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer?
    Paolo Maione
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Avellino 83100, Italy
    Lung Cancer 66:8-14. 2009
    ..Moreover we try to hypothesize a possible correlation between these two phenomena and to give suggestions on the prospective evaluation of this hypothetical correlation in the next future...
  71. doi request reprint Combined chemo-radiotherapy for locally advanced non-small cell lung cancer: current status and future development
    Cesare Guida
    Division of Radiotherapy, S G Moscati Hospital, Avellino, Italy
    Crit Rev Oncol Hematol 68:222-32. 2008
    ....
  72. ncbi request reprint Adjuvant chemotherapy in elderly patients with non-small-cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Cancer Control 14:57-62. 2007
    ..More than two thirds of patients who die of lung cancer in the United States are over 65 years of age. More than 50% of lung cancer patients are diagnosed over the age of 65 and about 30% over the age of 70...
  73. ncbi request reprint Responsiveness of skin metastases to CMF in a patient with urothelial carcinoma of the bladder: a case report
    Gerardo Rosati
    UO Oncologia Medica, Ospedale S Carlo, Potenza, Italy
    Tumori 89:85-7. 2003
    ..The improvement in cutaneous lesions and pain reduction obtained prompt further exploration of the activity of this regimen in a second-line approach...
  74. ncbi request reprint Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 2:221-9. 2007
    ....
  75. pmc The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer
    Clorinda Schettino
    Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi and A Lanzara, Second University of Naples, School of Medicine Via S Pansini 5, 80131 Naples, Italy
    Curr Genomics 9:252-62. 2008
    ..In this review we will discuss the potential role of pharmacogenomic approaches to guide the medical treatment of early stage NSCLC...
  76. doi request reprint Pattern of care for advanced non-small cell lung cancer in the era of histology-based treatment: a survey of the Italian Association of Thoracic Oncology (AIOT)
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Lung Cancer 67:339-42. 2010
    ..The survey included 16 items with multiple answers: 4 regarding the professional characteristics of each member, 9 the first-line treatment, and 3 the second-line therapy...
  77. doi request reprint Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis
    Antonio Rossi
    Division of Medical Oncology, SG Moscati Hospital, Città Ospedaliera, Contrada Amoretta 8, 83100 Avellino, Italy arossi
    Lung Cancer 70:119-28. 2010
    ....
  78. ncbi request reprint Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues
    Emilio Bria
    Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy
    Expert Opin Biol Ther 8:1963-71. 2008
    ..This result has been achieved in all disease settings, by increasing overall survival in early stage and advanced disease and by increasing pathological complete responses in neoadjuvant disease...
  79. ncbi request reprint Synchronous bilateral retinal metastases from lung adenocarcinoma
    Antonio Rossi
    UO Oncologia Medica, Azienda Ospedaliera, SG Moscati, Avellino, Italy
    Tumori 91:287-9. 2005
    ..The patient's prognosis was worsened by the onset of the retinal metastases and he died three months later...
  80. ncbi request reprint Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
    Marina Chiara Garassino
    J Clin Oncol 26:2600; author reply 2601-2. 2008
  81. ncbi request reprint Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
    Cesare Gridelli
    J Natl Cancer Inst 95:362-72. 2003
    ..We compared the effectiveness and toxicity of the combination of vinorelbine plus gemcitabine with those of each drug given alone in an open-label, randomized phase III trial in elderly patients with advanced NSCLC...
  82. ncbi request reprint First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study
    Bruno Daniele
    Medical Oncology, Clinical Trial Office, National Cancer Institute of Naples, Italy
    J Clin Gastroenterol 36:228-33. 2003
    ....
  83. ncbi request reprint A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Potenza, Italy
    Oncology 62:209-15. 2002
    ....
  84. ncbi request reprint Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study
    Cesare Gridelli
    Oncologia Medica B, Istituto Nazionale Tumori, Napoli, Italy
    Lung Cancer 36:327-32. 2002
    ..The primary end-point of the trial was the objective response rate. Twenty-three responses among 37 patients were considered necessary to proceed to a phase III trial...
  85. ncbi request reprint Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Potenza, Italy
    Anticancer Res 23:2981-5. 2003
    ....
  86. ncbi request reprint Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure
    Cesare Gridelli
    J Thorac Oncol 2:96-8. 2007
  87. pmc Supportive care in patients with advanced non-small-cell lung cancer
    M Di Maio
    National Cancer Institute Clinical Trials Unit, Naples
    Br J Cancer 89:1013-21. 2003
    ..Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults...
  88. ncbi request reprint Paclitaxel plus bevacizumab for metastatic breast cancer
    Antonio Rossi
    N Engl J Med 358:1637; author reply 1637-8. 2008
  89. ncbi request reprint Single-agent chemotherapy for the treatment of elderly patients with advanced non-small-cell lung cancer: what is the best drug?
    Cesare Gridelli
    J Clin Oncol 25:1444-5; author reply 1446. 2007
  90. ncbi request reprint Chemotherapy of advanced NSCLC in the elderly
    Cesare Gridelli
    Divisione di Oncologia Medica, Azienda Ospedaliera SG Moscati, Avellino
    Tumori 88:S143-4. 2002
  91. ncbi request reprint Corticosteroids underemployment in delayed chemotherapy-induced nausea and emesis with poor adherence to American Society of Clinical Oncology guidelines: is this a reasonable clinical choice for the elderly?
    Cesare Gridelli
    J Clin Oncol 21:4066-7; author reply 4067-8. 2003
  92. ncbi request reprint Thalidomide in small-cell lung cancer: is it a tombstone?
    Antonio Rossi
    J Clin Oncol 26:160; author reply 160. 2008
  93. ncbi request reprint Treatment of non-small cell lung cancer and targeted therapies: where are we?
    Cesare Gridelli
    Curr Opin Oncol 17:114-7. 2005
  94. ncbi request reprint Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer
    Antonio Rossi
    Institute of Neurobiology and Molecular Medicine, Consiglio Nazionale delle Ricerche, Rome, Italy
    Cancer Res 66:7678-85. 2006
    ....